Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

CASE:RMDA Stock Report

Market Cap: ج.م5.0b

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E Past Earnings Performance

Past criteria checks 2/6

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E has been growing earnings at an average annual rate of 21.9%, while the Pharmaceuticals industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 20.1% per year. Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E's return on equity is 15.7%, and it has net margins of 11.5%.

Key information

21.9%

Earnings growth rate

22.3%

EPS growth rate

Pharmaceuticals Industry Growth9.8%
Revenue growth rate20.1%
Return on equity15.7%
Net Margin11.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CASE:RMDA Revenue, expenses and earnings (EGP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,3192665330
30 Jun 242,1012275170
31 Mar 241,9872144890
31 Dec 231,9222234660
30 Sep 231,7792264430
30 Jun 231,6152204130
31 Mar 231,5332243970
31 Dec 221,4842293820
30 Sep 221,4872543490
30 Jun 221,4202293340
31 Mar 221,3212073100
31 Dec 211,2461663030
30 Sep 211,1401362830
30 Jun 211,0601152730
31 Mar 211,0101062670
31 Dec 20960972600
30 Sep 209471192530
30 Jun 209471052300
31 Mar 20921942090
31 Dec 19894821890
30 Sep 19853851720
30 Jun 19815901720
31 Mar 198101101650
31 Dec 188061291570
31 Dec 17628891200
31 Dec 1638227970
31 Dec 1527810770

Quality Earnings: RMDA has high quality earnings.

Growing Profit Margin: RMDA's current net profit margins (11.5%) are lower than last year (12.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RMDA's earnings have grown significantly by 21.9% per year over the past 5 years.

Accelerating Growth: RMDA's earnings growth over the past year (17.7%) is below its 5-year average (21.9% per year).

Earnings vs Industry: RMDA earnings growth over the past year (17.7%) did not outperform the Pharmaceuticals industry 37.9%.

Return on Equity

High ROE: RMDA's Return on Equity (15.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 19:23
End of Day Share Price 2024/12/29 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eman MareeArab African International Securities
Ahmed RashadBeltone Financial
Aly AdelBeltone Financial